Form 8.3 -HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Form 8.3 -GlobeNewswireJanuary 2, 2020ReblogShareTweetShare                FORM 8.3IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION Name of person dealing (Note 1) State Street Global Advisors & Affiliates
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.01 common stock
Date of dealing 31st December 2019
2. INTERESTS AND SHORT POSITIONS(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)   Long Short
Number (%) Number (%)
(1) Relevant securities 68,962,918
4.66322%
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total 68,962,918
4.66322%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities N/A
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total N/A       3. DEALINGS (Note 4)(a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 1,900 88.54
Purchase 400 88.54
Purchase 200 88.54
Purchase 400 88.54
Purchase 340 88.54
Purchase 300 88.54
Purchase 11,200 88.54
Purchase 100 88.54
Purchase 37 88.10
Purchase 191 88.10
Purchase 62 88.54
Purchase 357 88.54
Purchase 252,760 88.54
Purchase 17,847 88.54
Purchase 1,392 88.54
Purchase 96 88.54
Purchase 3,564 88.54
Purchase 10,920 88.54
Purchase 3,640 88.54
Purchase 721 88.54
Purchase 412 88.54
Purchase 2,870 88.54
Purchase 39 88.54
Purchase 400 88.54
Sale 2,000 87.93
Sale 4,200 88.54
Sale 400 88.54
Sale 200 88.54
Sale 5,800 88.54
Sale 400 88.34
Sale 400 88.54
Sale 11,200 88.54
Sale 103,100 88.54
Sale 107,900 88.35
Sale 4,600 88.54
Sale 14,100 88.11
Sale 400 88.54
Sale 900 88.54
Sale 37,400 88.54  (b) Derivatives transactions (other than options transactions) Product name, e.g. CFD Nature of transaction
(Note 6) Number of relevant securities
(Note 7) Price per unit
(Note 5)
N/A       (c) Options transactions in respect of existing relevant securities(i) Writing, selling, purchasing or varying Product name, e.g. call option Writing, selling, purchasing  varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
N/A             (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
N/A     (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
N/A     4. OTHER INFORMATIONAgreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
N/A
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 01st January 2020
Contact name Colin Fernandes
Telephone number
020 33956221
If a connected EFM, name of offeree/offeror with which connected N/A
If a connected EFM, state nature of connection (Note 10) N/A                 FORM 8.3IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION Name of person dealing (Note 1) State Street Global Advisors & Affiliates
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.01 common stock
Date of dealing 31st December 2019
2. INTERESTS AND SHORT POSITIONS(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)   Long Short
Number (%) Number (%)
(1) Relevant securities 68,962,918
4.66322%
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total 68,962,918
4.66322%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities N/A
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total N/A       3. DEALINGS (Note 4)(a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 1,900 88.54
Purchase 400 88.54
Purchase 200 88.54
Purchase 400 88.54
Purchase 340 88.54
Purchase 300 88.54
Purchase 11,200 88.54
Purchase 100 88.54
Purchase 37 88.10
Purchase 191 88.10
Purchase 62 88.54
Purchase 357 88.54
Purchase 252,760 88.54
Purchase 17,847 88.54
Purchase 1,392 88.54
Purchase 96 88.54
Purchase 3,564 88.54
Purchase 10,920 88.54
Purchase 3,640 88.54
Purchase 721 88.54
Purchase 412 88.54
Purchase 2,870 88.54
Purchase 39 88.54
Purchase 400 88.54
Sale 2,000 87.93
Sale 4,200 88.54
Sale 400 88.54
Sale 200 88.54
Sale 5,800 88.54
Sale 400 88.34
Sale 400 88.54
Sale 11,200 88.54
Sale 103,100 88.54
Sale 107,900 88.35
Sale 4,600 88.54
Sale 14,100 88.11
Sale 400 88.54
Sale 900 88.54
Sale 37,400 88.54  (b) Derivatives transactions (other than options transactions) Product name, e.g. CFD Nature of transaction
(Note 6) Number of relevant securities
(Note 7) Price per unit
(Note 5)
N/A       (c) Options transactions in respect of existing relevant securities(i) Writing, selling, purchasing or varying Product name, e.g. call option Writing, selling, purchasing  varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
N/A             (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
N/A     (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
N/A     4. OTHER INFORMATIONAgreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
N/A
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 02nd January 2020
Contact name Colin Fernandes
Telephone number
020 33956221
If a connected EFM, name of offeree/offeror with which connected N/A
If a connected EFM, state nature of connection (Note 10) N/A  ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSecurities agents sue 2 SC utility execs over nuclear fraudAssociated PressSteven Seagal fined in US over cryptocurrency promotionAFPA Note On Plc Uutechnic Group Oyj's (HEL:UUTEC) ROE and Debt To EquitySimply Wall St.Look at These 3 Invesco Mutual FundsZacksZacks.com featured highlights include: PulteGroup, SYNNEX, Republic Services, Lam Research and LeidosZacksRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDocuSign ‘Makes A Bet’ On AI With $188M Buy of Seal SoftwareCrunchbaseDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video